Is Sanofi destined to be 'small player' in MS?

February 6, 2012 | By Tracy Staton
Email LinkedIn
Tools

Sanofi ($SNY) CEO Chris Viehbacher (photo) is talking up trial results on his multiple sclerosis hopeful Lemtrada, acquired in his buyout of Genzyme. But advances by other companies are making it difficult for Sanofi to impress analysts with its own prospects. Report

Filed Under

, , ,

Comments

Press Releases

Featured Jobs